Integrin αvβ3-targeted cancer therapy

Drug Development Research

Volumn 69, Issue 6, 2008, Pages 329-339

  Liu, Zhaofei ^a,b   Wang, Fan ^b   Chen, Xiaoyuan ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PEKING UNIVERSITY   (China)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Angiogenesis; Anti angiogenic therapy; Integrin v 3; Metastasis

Indexed keywords

ABCIXIMAB; ABEGRIN; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CILENGITIDE; CNTO 95; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DISINTEGRIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; MACROGOL; MEDI 523; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; OSTEOPROTEGERIN; POLYETHYLENEIMINE; S 247; SC 68448; SCH 221153; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITAXIN I; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR BLOCKING AGENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER INHIBITION; CANCER RESEARCH; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 57749090308     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20265     Document Type: Review

References (89)

1. vbeta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270-6279.
2. Alghisi GC, Raegg C. 2006. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 13:113-135.
3. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. 2006. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 4:299-302.
4. Bertilaccio MTS, Grioni M, Sutherland BW, Degl'innocenti E, Freschi M, Jachetti E, Greenberg NM, Corti A, Bellone M. 2008. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate 68:1105-1115.
5. Bosch B, Clotet-Codina I, Blanco J, Pauls E, Coma G, Cedeno S, Mitjans F, Llano A, Bofill M, Clotet B, Piulats J, Este JA. 2006. Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Res 69:173-180.
6. Brooks PC, Clark RA, Cheresh DA. 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571.
7. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. 1995. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822.
8. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263-4272.
9. Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH. 2004. Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin. Mol Cancer Ther 3:1593-1604.
10. Cai W, Chen X. 2006. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6:407-428.
11. Calvete JJ, Moreno-Murciano MP, Theakston RDG, Kisiel DG, Marcinkiewicz C. 2003. Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering. Biochem J 372:725-734.
12. Cao L, Du P, Jiang S-H, Jin G-H, Huang Q-L, Hua Z-C. 2008. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther 7:851-858.
13. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407:249-257.
14. Carron CP, Meyer DM, Engleman VW, Rico JG, Ruminski PG, Ornberg RL, Westlin WF, Nickols GA. 2000. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 165:587-598.
15. vbeta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 58:1930-1955.
16. Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, Sharp C, Shahied-Arruda L, Doshi P, Nakada MT, Anderson GM. 2008. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 25:139-148.
17. Cheresh DA. 1987. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 84:6471-6475.
18. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB. 2006. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 94:1621-1626.
19. Cohen SA, Trikha M, Mascelli MA. 2000. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res 6:163-174.
20. Colevas AD, Scharf O, Schoenfeldt M. 2004. Clinical trials referral resource. Current clinical trials of cilengitide, an alphav antagonist in clinical development as an anticancer agent. Oncology 18:1778-1781.
21. Colomer R. 2004. Gemcitabine and paclitaxel in metastatic breast cancer: a review. Oncology 18(Suppl 12):8-12.
22. Corti A, Ponzoni M. 2004. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci 1028:104-112.
23. Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, Marty M, Faivre S. 2008. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 26:35-43.
24. Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, Bunting S, Lazarus RA. 1990. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 87:2471-2475.
25. Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. 2008. Pharmacology of the novel antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): observation of a u-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 14:2137-2144.
26. Eble JA, Haier J. 2006. Integrins in cancer treatment. Curr Cancer Drug Targets 6:89-105.
27. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
28. Folkman J. 1995a. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27-31.
29. Folkman J. 1995b. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763.
30. Folkman J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(Suppl 16):15-18.
31. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502.
32. Fuchs U, Borkhardt A. 2007. The application of siRNA technology to cancer biology discovery. Adv Cancer Res 96:75-102.
33. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. 1988. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem 263:19827-19832.
34. Guo W, Giancotti FG. 2004. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816-826.
35. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. 2000. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6:3056-3061.
36. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. 2007. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 12, 1974), in patients with advanced solid tumors. Ann Oncol 18:1400-1406.
37. Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, Edwards S, Onthank D, Silva P, Yalamanchili P, Robinson S, Lazewatsky J, Barrett J, Bozarth J. 2003. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 18:627-641.
38. 3) integrin, +/-dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Immunother 28:643-644.
39. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-2407.
40. Hood JD, Cheresh DA. 2002. Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100.
41. 3 antagonists for anti-angiogenic cancer treatment. Recent Patents Anticancer Drug Discov 2:143-158.
42. Huang TF. 1998. What have snakes taught us about integrins? Cell Mol Life Sci 54:527-540.
43. Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. 1987. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. J Biol Chem 262:16157-16163.
44. Hynes RO. 2002. Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687.
45. Jain RK. 2001. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989.
46. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62.
47. 3 integrin binding peptides in a nude mouse model. Cancer Res 62:6146-6151.
48. Jin H, Varner J. 2004. Integrins: roles in cancer development and as treatment targets. Br J Cancer 90:561-565.
49. Kumar CC. 2003. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4:123-131.
50. vbeta5 integrin receptor antagonist. Cancer Res 61:2232-2238.
51. Lipscomb EA, Dugan AS, Rabinovitz I, Mercurio AM. 2003. Use of RNA interference to inhibit integrin (alpha6beta4)-mediated invasion and migration of breast carcinoma cells. Clin Exp Metastasis 20:569-576.
52. Lu PY, Woodle MC. 2008. Delivering small interfering RNA for novel therapeutics. Methods Mol Biol 437:93-107.
53. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE. 2008. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26:919-924.
54. McCaffrey AP, Meuse L, Pham T-TT, Conklin DS, Hannon GJ, Kay MA. 2002. RNA interference in adult mice. Nature 418:38-39.
55. McLane MA, Kuchar MA, Brando C, Santoli D, Paquette-Straub CA, Miele ME. 2001. New insights on disintegrin-receptor interactions: eristostatin and melanoma cells. Haemostasis 31:177-182.
56. Meerovitch K, Bergeron F, Leblond L, Grouix B, Poirier C, Bubenik M, Chan L, Gourdeau H, Bowlin T, Attardo G. 2003. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vascul Pharmacol 40:77-89.
57. Minea R, Swenson S, Costa F, Chen TC, Markland FS. 2005. Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent. Pathophysiol Haemost Thromb 34:177-183.
58. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J. 2000. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 87:716-723.
59. Mitjans F, Sander D, Adán J, Sutter A, Martinez JM, Jäggle CS, Moyano JM, Kreysch HG, Piulats J, Goodman SL. 1995. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 108 2825-2838.
60. Mullamitha SA, Ton NC, Parker GJM, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Kiao Q, Prabhakar U, Lang Z, Corringham RB, Beckman RA, Jayson GC. 2007. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128-2135.
61. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. 2007. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657.
62. Nisato RE, Tille J-C, Jonczyk A, Goodman SL, Pepper MS. 2003. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6:105-119.
63. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. 2001. Pilot study of vitaxin - an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 92:1347-1348.
64. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. 2001. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16:125-132.
65. vbeta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J 16:2000-2002.
66. Raguse J-D, Gath HJ, Bier J, Riess H, Oettle H. 2004. Cilengitide (EMD 12, 1974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40:228-230.
67. Ruoslahti E, Pierschbacher MD. 1986. Arg-Gly-Asp: a versatile cell recognition signal. Cell 44:517-518.
68. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. 2004. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 64:7150-7155.
69. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF. 1991. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 266:9359-9362.
70. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. 2004. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149.
71. Schwartz MA. 2001. Integrin signaling revisited. Trends Cell Biol 11:466-470.
72. Sharma RA, Harris AL, Dalgleish AG, Steward WP, O'Byrne KJ. 2001. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2:726-732.
73. Shebuski RJ, Ramjit DR, Bencen GH, Polokoff MA. 1989. Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine- aspartic acid-containing peptide from the venom of the viper Bitis arietans. J Biol Chem 264:21550-21556.
74. Smith JW. 2003. Cilengitide Merck. Curr Opin Invest Drugs 4:741-745.
75. Strieth S, Eichhorn ME, Sutter A, Jonczyk A, Berghaus A, Dellian M. 2006. Antiangiogenic combination tumor therapy blocking alphav-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 119:423-431.
76. Swenson S, Costa F, Minea R, Sherwin RP, Ernst W, Fujii G, Yang D, Markland FS. 2004. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 3:499-511.
77. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE. 2002. alpha v-Integrin antagonist EMD 12, 1974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98:690-697.
78. vbeta3 integrins. Circulation 98:1085-1091.
79. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT. 2004. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110:326-335.
80. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. 2002. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62:2824-2833.
81. Van der Flier A, Sonnenberg A. 2001. Function and interactions of integrins. Cell Tissue Res 305:285-298.
82. Van Laarhoven HWM, Gambarota G, Heerschap A, Lok J, Verhagen I, Corti A, Toma S, Gallo Stampino C, van der Kogel A, Punt CJA. 2006. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs 24:27-36.
83. Varner JA, Nakada MT, Jordan RE, Coller BS. 1999. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis 3:53-60.
84. 3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res (in press).
85. Wang H, Chen K, Cai W, Li Z, He L, Kashefi A, Chen X. 2008. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther 7:1044-1053.
86. Wilder RL. 2002. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61(Suppl 2):96-99.
87. Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD. 1998. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci USA 95:6037-6042.
88. Zarovni N, Monaco L, Corti A. 2004. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. Hum Gene Ther 15:373-382.
89. Zhou X-D, Jin Y, Chen R-Q, Lu Q-M, Wu J-B, Wang W-Y, Xiong Y-L. 2004. Purification, cloning and biological characterization of a novel disintegrin from Trimeresurus jerdonii venom. Toxicon 43:69-75.